AKBM: Q2 2025 delivered double-digit growth, margin expansion, and robust segment performance

About this update from Aker Biomarine Asa

Q2 2025 saw 12% revenue growth and 41% higher adjusted EBITDA, led by strong human health and consumer health segments. Operational leverage, cost reallocation, and product innovation drove margin gains, while a $15 million impairment was taken on the protein plant due to tariff uncertainty.Based on This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Aker Biomarine Asa